Pharmaceuticals

C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework

CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel of experts from the Sichuan Provincial Center for Drug Evaluation and the National Defense Science and Industry Adminis...

2026-06-25 11:33

Dimora Medical has joined the NPIAP Corporate Advisory Council as an Honorary Member

NEW YORK, June 24, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, has officially joined the National Pressure Injury Advisory Panel (NPIAP) as a corporate member, marking a new step in its engagement with the global clinical community focused on pre...

2026-06-25 11:24

ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific

Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies SHANGHAI, June 25, 2026 /PRNewswire/ -- ATLATL Innovation Center ("ATLATL"), a global innovation platform for life science research and development, and Samsung Bioepis C...

2026-06-25 07:30 466

Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region

ABU DHABI, UAE, June 25, 2026 /PRNewswire/ -- As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a  collaboration with global pharmaceutical leader MSD (Merck & Co., Inc., Rahway, New...

2026-06-25 03:15 652

HKeyBio Debuts HKEY-ExE™ 1.0 to Address Preclinical Bottlenecks in EoE and EgE Drug Development

The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical contract research organization focused on autoimmune an...

2026-06-24 21:18 746

HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and...

2026-06-24 20:36 595

Tarek Samad appointed EVP, Head of Research & Development at Lundbeck

VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) effective 1 September 2026. Tarek Samad succeeds Johan ...

2026-06-24 18:19 766

Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

* Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart * Eptinezumab data explore patient-centered outcomes in chronic migra...

2026-06-24 16:08 634

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan He...

2026-06-24 15:07 925

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production camp...

2026-06-24 14:39 711

Finetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghai

System delivers filling volume accuracy within ±2–3%, output of 15,600 capsules per hour, and in-line rejection rates below 0.2%, addressing critical dosing consistency requirements for pharmaceutical and nutraceutical manufacturers SHANGHAI, June 24, 2026 /PRNewswire/ -- Finetech Pharmaceutical ...

2026-06-24 13:57 574

Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhib...

2026-06-24 11:53 603

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical co...

2026-06-24 09:00 572

Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

SHANGHAI, June 23, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative L...

2026-06-24 08:00 689

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement withNuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the ...

2026-06-23 21:17 834

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than doubled the company's laboratory footprint, expanding the ...

2026-06-23 21:12 524

Fair Play Menarini International Award

Diego Milito and Emilio Butragueño among the winners of the 30th edition FLORENCE, Italy, June 23, 2026 /PRNewswire/ -- The list of winners of the 30th Fair Play Menarini International Award, scheduled forJuly 2 in Florence, continues to include great legends of world sport. Among the champions w...

2026-06-23 18:29 559

Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

* Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug ...

2026-06-23 18:10 833

CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation

SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary entries.

2026-06-23 08:00 1972

DoH and Sanofi Partner to Advance Vaccine Innovation

ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partner...

2026-06-23 07:47 2070
12345 ... 344